Vitamin D3 Supplementation Reduces Migraine Days, Results from Randomized Placebo-controlled Trial

Primary tabs

SCIENCE
Vitamin D3 Supplementation Reduces Migraine Days, Results from Randomized Placebo-controlled Trial
Key Take-Away: 

Optimal Vitamin D levels are crucial to generate the “happy” brain chemical serotonin and curtail the Migraine-producing inflammation and oxidative stress. In this trial, the treatment group had notable reductions in the number of headache changes and a more significant decrease in the migraine frequency. Also, a higher response was observed in the vitamin D3 group.

Introduction:

Vitamin D levels have been connected to individual pain states, including migraine. This study investigated whether vitamin D supplementation is beneficial for adult patients with migraine.

 

Methods:

A randomized, double-blinded, placebo-controlled parallel trial was conducted in migraine patients (36 women and 12 men, 18-65 years of age). A 4-week baseline period was performed before randomization to 24 weeks of treatment. The participants were allocated to receive D3-Vitamin (n = 24; 18 women and 6 men, 100 μg/day D3-Vitamin) or placebo (n = 24; 18 women and 6 men). Self-reported diaries assessed migraine attacks and related symptoms. Response rate (i.e. having a 50% or more significant reduction in migraine frequency from baseline to week 24), change in migraine severity, and the number of migraine days were noted down. The changes in the migraine-related symptoms, HIT-6TM scores, and pain sensitivity tests (pressure pain threshold and temporal summation) were also estimated. The serum levels of both 25 (OH)D and 1,25 (OH)2D were examined from baseline to week 24.

 

Results:

The number of headache days switched from 6.14 ± 3.60 in the treatment group and 5.72 ± 4.52 in the placebo group at baseline to 3.28 ± 3.24 and 4.93 ± 3.24 towards the end of the trial. Migraine patients on D3-Vitamin indicated a significant decrease in migraine frequency from baseline to week 24 compared with placebo. But, there was no substantial change in migraine severity, pressure pain thresholds, or temporal summation. During the first 12 weeks of treatment, 25(OH)D levels increased significantly for the D3-Vitamin group. No significant change was observed in 1,25(OH)2D. There were no side-effects.

 

Conclusions:

D3-Vitamin was superior to placebo in decreasing migraine days in migraine patients. More extensive studies are required to confirm that vitamin D3 might be one of the prophylactic options for adult patients with migraine.

Source

Current Medical Research and Opinion

Link:

https://www.ncbi.nlm.nih.gov/pubmed/30182753

Original title of article:

A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D3 supplementation in adult patients with migraine

Authors:

Gazerani P et al.

Therapeutic, Vitamin D3, Migraine, Head, Randomized double-blinded placebo-controlled parallel trial, HIT-6TM scores, Pain sensitivity tests
Log in or register to post comments